BUTROPIUM BROMIDE

Details

Stereochemistry	MIXED
Molecular Formula	C28H38NO4.Br
Molecular Weight	532.51
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Br-].CCCCOC1=CC=C(C[N@+]2(C)[C@H]3CC[C@@H]2C[C@@H](C3)OC(=O)[C@H](CO)C4=CC=CC=C4)C=C1

InChI

InChIKey=JABDOYKGZCPHPX-XSCYYCMVSA-M

InChI=1S/C28H38NO4.BrH/c1-3-4-16-32-25-14-10-21(11-15-25)19-29(2)23-12-13-24(29)18-26(17-23)33-28(31)27(20-30)22-8-6-5-7-9-22;/h5-11,14-15,23-24,26-27,30H,3-4,12-13,16-20H2,1-2H3;1H/q+1;/p-1/t23-,24+,26+,27-,29?;/m1./s1

HIDE SMILES / InChI

Description
Sources: http://eisai.jp/medical/products/di/EPI/CLP_C-T-G_EPI.pdf
Curator's Comment: Description was created based on several sources, including http://www.mims.com/malaysia/drug/info/coliopan and http://www.genome.jp/dbget-bin/www_bget?D01491

Butropium Bromide is an anticholinergic and an antispasmodic. It is a Muscarinic receptor antagonist. The drug is used for remission of spasmodic pain in the following diseases: gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia). It is marketed in Japan under the brand name Coliopan.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 160 Target ID: CHEMBL2094109 Sources: http://www.genome.jp/dbget-bin/www_bget?D01491	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
Spasmodic pain in gastritis 2 Sources: http://eisai.jp/medical/products/di/EPI/CLP_C-T-G_EPI.pdf	Palliative	Approved 8429	Coliopan Approved Use Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia) Launch Date 1974
Spasmodic pain in gastric ulcer 2 Sources: http://eisai.jp/medical/products/di/EPI/CLP_C-T-G_EPI.pdf	Palliative	Approved 8429	Coliopan Approved Use Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia) Launch Date 1974
Spasmodic pain in cholelithiasis 2 Sources: http://eisai.jp/medical/products/di/EPI/CLP_C-T-G_EPI.pdf	Palliative	Approved 8429	Coliopan Approved Use Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia) Launch Date 1974

PubMed

Title	Date	PubMed
Endoscopic manometry of the sphincter of Oddi in dogs. Pharmacological effects of anticholinergic and selective antimuscarinic agents.	1987 May	3449985

Patents

Sample Use Guides

In Vivo Use Guide

Capsules 5 mg: The usual adult dosage for oral use is 6 capsules (30 mg of butropium bromide) daily in three divided doses. Tablets 10 mg: The usual adult dosage for oral use is 3 tablets (30 mg of butropium bromide) daily in three divided doses. Granules 2 %: The usual adult dosage for oral use is 1.5 g (30 mg of butropium bromide) daily in three divided doses.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

BUTROPIUM BROMIDE

Official Name

English

8-(P-BUTOXYBENZYL)-3.ALPHA.-HYDROXY-1.ALPHA.H,5.ALPHA.H-TROPANIUM BROMIDE (-)-TROPATE

Common Name

English

8-AZONIABICYCLO(3.2.1)OCTANE, 8-((4-BUTOXYPHENYL)METHYL)-3-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-8-METHYL-, BROMIDE, (3(S)-ENDO)-

Common Name

English

COLIOPAN

Brand Name

English

BUTROPIUM BROMIDE [MART.]

Common Name

English

BUTROPIUM BROMIDE [JAN]

Common Name

English

BUTROPIUM BROMIDE [MI]

Common Name

English

Butropium bromide [WHO-DD]

Common Name

English

butropium bromide [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29704